 |
인쇄하기
취소
|
Sutent set to debut in Korea
Pfizer Korea said on March 1 that Sutent (sunitinib malate) capsules made its debut in Korea.
Sutent, which was approved by the Korea Food and Drug Administration on July last year, is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs).
Sutent is indicated for the treatment of gastrointestinal stromal tumo...
Sutent, which was approved by the Korea Food and Drug Administration on July last year, is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs).
Sutent is indicated for the treatment of gastrointestinal stromal tumo...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.